Personalizing smoking cessation pharmacotherapy using neuroaffective reactivity profiles: A randomized controlled trial
Addiction · 2026
DOI: 10.1111/add.70354 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Addiction, 2026. Verfasst von Francesco Versace und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Smoking Cessation, Varenicline, Smoking Cessation Agents, Motivation. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: State of Texas Permanent Health Funds awarded to the University of Texas MD Anderson Cancer Center, Cancer Prevention and Research Institute of Texas, The University of Texas MD Anderson Lung Cancer Moonshot Program.
Abstract (Originalsprache)
Background and aims By assessing neuroaffective response to motivationally relevant cues before a quit attempt, we have shown that smokers who attribute greater incentive salience to cigarette‐related cues than non‐cigarette‐related rewards (Sign‐trackers, ST) benefit more from varenicline compared with smokers with the opposite neuroaffective reactivity profile (Goal‐trackers, GT). This proof‐of‐concept trial aimed to extend this work by testing whether the efficacy of varenicline relative to nicotine replacement treatment differs across the two neuroaffective reactivity profiles.
Design
A 2‐group, double‐blind, randomized controlled clinical trial with stratification on ST versus GT classification (based on baseline‐assessed neuroaffective reactivity profiles) for adults seeking to quit smoking using varenicline or nicotine replacement therapy (NRT).
Setting
Hospital‐based outpatient clinic specializing in smoking cessation treatment, located in Houston, Texas, USA.
Participants
158 community volunteers (78 randomized to varenicline and 80 to NRT): 18–75 years of age, smoking 5 or more cigarettes/day and without severe comorbid psychiatric disorders, uncontrolled medical illnesses or contraindications for pharmacotherapy. Interventions and comparators Twelve weeks of varenicline or NRT combined with brief cessation counseling.
Measurements
Primary outcome: continuous smoking abstinence over the last 4 weeks of treatment. Secondary outcomes: continuous abstinence at 3‐ and 6‐month follow‐ups.
Findings
Using a Bayesian approach, we estimated the probability that an interaction between treatment and neuroaffective profile exists. We pre‐specified a probability above 80% as evidence for an interaction. Logistic regression indicated a 92.7% probability that an interaction between treatment and neuroaffective profile exists, exceeding the pre‐specified threshold. Individuals with the ST profile responded better to varenicline than to NRT. At the end of treatment, the ST group showed a 35% Absolute Risk Difference (ARD) favoring varenicline over NRT (absolute cessation rates: 47% and 11%, respectively). In contrast, among individuals with the GT profile, the benefit of varenicline was smaller, with an ARD of 13% (absolute cessation rates of 29% for varenicline and 17% for NRT). The varenicline advantage for the ST group persisted at 3‐ and 6‐month follow‐ups.
Conclusions
Smokers seeking to quit who attribute greater incentive salience to cigarette‐related cues than non‐cigarette‐related rewards benefit more from varenicline than from nicotine replacement therapy. These findings support using neuroaffective biomarkers to inform personalized smoking cessation interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Center for Clinical Research and Evidence-Based Medicine, Department of Pediatrics, The University of Texas Health Science Center at Houston, Houston, TX, USA.
- Collaboration for STEM Education and Outreach, Department of Teaching and Learning, Vanderbilt University, Nashville, TN, USA.
ORCID-Profile: Francesco Versace, Maher Karam-Hage, Paul M Cinciripini
Förderung
- State of Texas Permanent Health Funds awarded to the University of Texas MD Anderson Cancer Center
- Cancer Prevention and Research Institute of Texas
- The University of Texas MD Anderson Lung Cancer Moonshot Program
- Cancer Prevention & Research Institute of Texas
- University of Texas MD Anderson Lung Cancer Moonshot Program
- NCI NIH HHS
- National Cancer Institute to the University of Texas MD Anderson Cancer Center
- National Cancer Institute
Zitieren
APA
Versace, F., Green, C. E., Cui, Y., Robinson, J. D., Deweese, M. M., Minnix, J. A., Kypriotakis, G., Kim, S., Karam-Hage, M., & Cinciripini, P. M. (2026). Personalizing smoking cessation pharmacotherapy using neuroaffective reactivity profiles: A randomized controlled trial. Addiction. https://doi.org/10.1111/add.70354
Vancouver
Versace F, Green CE, Cui Y, Robinson JD, Deweese MM, Minnix JA, et al. Personalizing smoking cessation pharmacotherapy using neuroaffective reactivity profiles: A randomized controlled trial. Addiction. 2026. doi:10.1111/add.70354
BibTeX
@article{Versace2026,
author = {Versace, Francesco and Green, Charles E and Cui, Yong and Robinson, Jason D and Deweese, Menton M and Minnix, Jennifer A and Kypriotakis, George and Kim, Seokhun and Karam-Hage, Maher and Cinciripini, Paul M},
title = {Personalizing smoking cessation pharmacotherapy using neuroaffective reactivity profiles: A randomized controlled trial},
journal = {Addiction},
year = {2026},
doi = {10.1111/add.70354}
}
EUVIMED